

# **Cardiovascular Evaluation for the over 40's Prior to Engaging in Moderate to High Intensity Sports**

**Dr. Azad Ghuran, Consultant Cardiologist**

## ***INTRODUCTION***

The benefits of regular physical exercise on the human body are multiple and indisputable. The improvements in cardiovascular (CV) risk profile associated with exercise are partly secondary to its positive impact on atherosclerotic risk factors such as blood pressure, lipid profile, body mass index, and insulin resistance<sup>1</sup>. There is a dose effect relationship between exercise and CV all-cause mortality, with a 20-30% reduction in adverse events compared with sedentary individuals<sup>2,3</sup>.

Paradoxically, the hemodynamic and metabolic stresses of intense and excessive exercise, may promote fatal arrhythmias and even myocardial infarction in some individuals with underlying undetected, subclinical cardiac diseases<sup>4</sup>. The causes of deaths are very much age-dependent and in young people, considered less than 35 years, the most common causes of death are inherited conditions such as the cardiomyopathies, ion channel disease, sudden arrhythmic death syndrome, coronary anomaly and myocarditis<sup>5</sup>. In athlete >35 years of age, more than 80% of all sudden cardiac death (SCD) is due to atherosclerotic coronary artery disease (CAD), and vigorous physical exertion is associated with an increased risk of SCD and acute myocardial infarction<sup>6</sup>. The individuals at greatest risk are those with little or no systematic training background. Exercise induced acute coronary syndrome results from atherosclerotic plaque rupture and thrombosis<sup>6</sup>. Greater than 50% of patients have no pre-existing symptoms or history of CAD<sup>7,8</sup>.

The concept of screening and recommendations for sport eligibility is to maximise benefits of exercise at the lowest risk. The early detection of advanced CAD in asymptomatic athletes, may potentially decrease CV mortality and morbidity through risk stratification, disease specific intervention and exercise modification<sup>9</sup>.

The 2020 European Society of Cardiology (ESC) guidelines on sports cardiology and exercise in patients with cardiovascular disease recommend pre-participation evaluation for cardiovascular disease in older athletes<sup>9</sup>. Acknowledging, that the evidence base for CV screening is limited and controversial for athletes >35 years of age, screening utilising a health questionnaire, ECG and examination, may discover undiagnosed cardiomyopathies, primary electrical disorders and subclinical CAD.

In recent years, there has been a drive to improve health and fitness in the population, resulting in an increase in amateur participation in sporting events such as half-marathons and marathons. Similarly, there is an expanding population of older veterans and amateur athletes competing in high-intensity events. The estimated prevalence of sport-related sudden death occurs in approximately 5 to 17 cases per million in the general population with a peak between the ages of 40-60 years of age<sup>10-13</sup>. The incidence of sports related sudden cardiac arrest is between 22-58 per million per year. The majority (94%) of all exercise related deaths in the community occur in middle age and older individuals engaging in recreational sports<sup>10</sup>. Consequently, pre-participation screening programmes in this age range of middle-aged/senior athletes engaging in either competitive or leisure-time sports is proposed as the optimal age range for cardiovascular risk assessment. The 40-year lower age recommendation also coincides with the NHS Health Check programme in England, which invites adults from 40-74 years for a cardiovascular health check<sup>14</sup>.

### ***OBJECTIVE OF THE PROPOSED SCREENING PROGRAMME***

Based on the above background, the objective of the proposed screening programme is to detect silent cardiovascular abnormalities in middle-aged/senior athletes, already practising, or who wishes to participate in leisure time sports, especially individuals naive to moderate to vigorous physical activity. The implementation of a pragmatic and practical screening programme algorithm to identify high-risk individuals can mitigate the risk of SCD and cardiovascular morbidity in middle-ages/senior athletes. As CAD accounts for the vast majority of fatalities in this age range, the proposed algorithm is focused mainly in detecting subclinical CAD, although other conditions such as cardiomyopathies, electrical disorders, valvular and structural heart disease can be detected during the screening process. Furthermore, cardiovascular risk prevention is in keeping with the NHS England agenda for treating Cardiovascular Disease<sup>15</sup>.

## ***COMPARISON TO OTHER RECOMMENDATIONS***

The American Heart Association science advisory committee recommends pre-participation screening for master competitive master athletes (defined as > 40 years old). Screening involves a history, physical examination, and maximal exercise testing of all men above 40 years (women > 50) with one additional risk factor and those with symptoms, as well as all master athletes above 65 years of age, regardless of risk factors or symptoms<sup>16</sup>. Our screening protocol also includes adult/senior nonprofessional active or sedentary individuals engaging in leisure-time physical/sports activities. We also selectively recommend further testing in individuals with higher risk of CAD according to the QRISK score.

## ***IDENTIFYING INDIVIDUALS AT HIGH RISK OF CORONARY ARTERY DISEASE AND CARDIOVASCULAR RISK ASSESSMENT***

### ***Health questionnaire***

Identifying individuals at high risk of coronary artery disease begins with a history and risk assessment. A history of chest pain or SOBE should raise suspicion of underlying CAD. Sudden cardiac arrest during sports activity in middle-age individuals is associated with a history of pre-existing heart disease (16%), cardiac risk factors for CAD (56%) and symptoms typical of cardiovascular disease in the prior week (36%)<sup>13</sup>. Therefore, a health questionnaire will be used in the proposed screening protocol, which is included in the index.

### ***Risk Scores***

Cardiovascular risk prediction models, such as the European Society of Cardiology Systematic Coronary Risk Evaluation (SCORE) calculator or the QRISK score can be used to determine the likelihood of subclinical CAD<sup>17, 18</sup>. These models take into consideration individual risk factors and medical conditions predisposing to coronary atherosclerosis. In the UK, General Practice Centres use the QRISK cardiovascular risk model<sup>18</sup>, which can easily be calculated using the electronic patient

records. Consequently, the QRISK score in the proposed screening algorithm will be used to determine low versus high cardiovascular risk for subclinical coronary artery disease (Figure 1).

### **Limitations of cardiovascular risk scores and role of CT coronary angiography**

Cardiovascular risk scores are based on epidemiological studies and probabilistic models are often used to try and estimate cardiovascular risk. These scores can underestimate in the young and overestimate in the elderly<sup>19</sup>. An alternative strategy is to directly screen for the disease rather than calculate the probabilistic risk scores. CT coronary angiography (CTCA) provides non-invasive information on coronary anatomy and atherosclerosis and provides better CV risk discrimination beyond traditional risk factors<sup>19-21</sup> and has been suggested as a promising tool for screening asymptomatic veteran athletes<sup>22</sup>. However, CTCA is costly, exposes the individual to a small amount of radiation on modern scanners, potential risk of contrast reactions, and suffers from a lack of outcome data in the athletic population. Nevertheless, there is emerging data that the early detection and implementation of preventative strategies may improve long-term cardiovascular benefits<sup>23</sup>. Consequently, the role of CTCA in the proposed screening programme will only be used in highly selected individuals.

### ***EXERCISE TOLERANCE TESTING (ETT)***

Exercise tolerance testing is low cost and can assess for ischaemic and arrhythmia changes, and BP response during exercise. Although the use of maximal ETT in asymptomatic healthy individuals with a low risk of cardiovascular events, has a low positive predictive value<sup>16, 24</sup>, in populations with risk factors for CAD, a positive exercise test has been shown to identify individuals with an increased risk of subsequent coronary events<sup>25, 26</sup>. In the Seattle Heart Watch Study, during the 5-year follow-up period, asymptomatic men with more than one coronary risk factor and more than two abnormal findings on ETT, had a 30 times higher risk for cardiac events<sup>27</sup>.

### ***Other IMAGING Modalities***

Current evidence suggests that the accuracy of all cardiac imaging modalities is insufficient to justify their use as primary screening modalities in athletes<sup>28</sup>. However, if any abnormalities are detected on exercise tolerance testing or on a CTCA, then either an exercise stress echocardiogram or perfusion

myocardial scan will be arranged to determine the burden of myocardial ischaemia, as they are locally available with expertise.

**Figure 1. QRISK cardiovascular risk calculator (<https://qrisk.org/three/>)**

**Welcome to the QRISK<sup>®</sup>3-2018 risk calculator <https://qrisk.org/three>**

This calculator is only valid if you do not already have a diagnosis of coronary heart disease (including angina or heart attack) or stroke/transient ischaemic attack.

[Reset](#) [Information](#) [Publications](#) [About](#) [Copyright](#) [Contact Us](#) [Algorithm](#) [Software](#) [UKCA](#)

**About you**

Age (25-84):

Sex: ☒ Male ☐ Female

Ethnicity:

UK postcode:

Postcode:

**Clinical information**

Smoking status:

Diabetes status:

Angina or heart attack in a 1st degree relative < 60? ☐

Chronic kidney disease (stage 3, 4 or 5)? ☐

Atrial fibrillation? ☐

On blood pressure treatment? ☐

Do you have migraines? ☐

Rheumatoid arthritis? ☐

Systemic lupus erythematosus (SLE)? ☐

Severe mental illness? (this includes schizophrenia, bipolar disorder and moderate/severe depression) ☐

On atypical antipsychotic medication? ☐

Are you on regular steroid tablets? ☐

A diagnosis of or treatment for erectile dysfunction? ☐

Leave blank if unknown

Cholesterol/HDL ratio:

Systolic blood pressure (mmHg):

Standard deviation of at least two most recent systolic blood pressure readings (mmHg):

Body mass index

Height (cm):

Weight (kg):

**Calculate risk**

**Welcome to the QRISK<sup>®</sup>3-2018 risk calculator**

Welcome to the QRISK<sup>®</sup>3-2018 Web Calculator. The QRISK<sup>®</sup>3 algorithm calculates a person's risk of developing a heart attack or stroke over the next 10 years. It presents the average risk of people with the same risk factors as those entered for that person.

The QRISK<sup>®</sup>3 algorithm has been developed by doctors and academics working in the UK National Health Service and is based on routinely collected data from many thousands of GPs across the country who have freely contributed data to the QResearch database for medical research.

QRISK<sup>®</sup>3 has been developed for the UK population, and is intended for use in the UK. All medical decisions need to be taken by a patient in consultation with their doctor. The authors and the sponsors accept no responsibility for clinical use or misuse of this score.

The science underpinning QRISK<sup>®</sup>3 has been published in the BMJ -- see the publications tab for details.

**What is the difference between QRISK<sup>®</sup>3 and QRISK<sup>®</sup>2?**

QRISK<sup>®</sup>3 includes more factors than QRISK<sup>®</sup>2 to help enable doctors to identify those at most risk of heart disease and stroke. These are:

- Chronic kidney disease, which now includes stage 3 CKD
- Migraine
- Corticosteroids
- Systemic lupus erythematosus (SLE)
- atypical antipsychotics
- severe mental illness
- erectile dysfunction
- a measure of systolic blood pressure variability

**Has QRISK<sup>®</sup>3 been validated?**

Yes. QRISK<sup>®</sup>3 has been validated on a separate group of practices from that used to develop the score and the performance is very good. See the academic paper for more details.

**Why change the name from QRISK<sup>®</sup>2 to QRISK<sup>®</sup>3?**

It's the same science and team behind the score, and the way that we intend it to be used remains exactly the same. In many ways it is very similar to our usual annual updates -- however, we thought that as we are introducing several new parameters, we'd upgrade its major version number.

**What will now happen to QRISK<sup>®</sup>2?**

QRISK<sup>®</sup>2-2017 will be the last version of QRISK<sup>®</sup>2 that we will produce. QRISK<sup>®</sup>3 will be the standard version of QRISK<sup>®</sup> shipped in our software development kits in 2018, so all implementations will become QRISK<sup>®</sup>3 in due course.

**But I want to carry on using QRISK<sup>®</sup>2...**

Although QRISK<sup>®</sup>2 is fine to use in a transition period, QRISK<sup>®</sup>3 is better. For several conditions QRISK<sup>®</sup>2 will underestimate people's risk. Plan to move to using QRISK<sup>®</sup>3 in an orderly fashion. Learn what the new parameters mean and embrace them!

## Proposed Pre-Participation Algorithm for cardiovascular assessment in asymptomatic individuals > 40 years

The methodology of how middle-aged and older individuals should be screened before engaging in regular physical activity is both complex and controversial. The proposed methodology employed in this screening programme is based on the recommendation from the 2020 ESC Guidelines on Sports Cardiology<sup>9</sup>. It is practical, patient-centred and based on the individual's cardiac risk profile and the intended level of physical activity. Individuals considered to be at risk will require further assessment.

### Phase I


Following preliminary evaluation from the self-assessment questionnaire, a physical examination to detect any relevant clinical findings such as an irregular pulse, elevated jugular venous pressure, blood pressure, and heart murmurs will be conducted followed by an ECG.

## ECG

The ECG will be interpreted within the context of the International recommendations for ECG interpretation in athletes<sup>29</sup>, recognising that the majority of screened individuals will be engaging in recreational/leisure time activities and therefore would be interpreted as in the general population. While the ECG increases the ability to detect underlying cardiovascular conditions, it has limited sensitivity and specificity in patients with anomalous coronary arteries, premature coronary atherosclerosis and aortopathies.

### Phase II (figure 2)

- In individuals with low CVD risk Score (QRISK3 score <5%), no cardiovascular risk factors, and physically active, then no further investigations are required, and can participate in sporting activities including competitive sports.
- In patients with an abnormal ECG; high CVD risk score (QRISK3  $\geq$  5%) or additional risk factors; sedentary with little physical activity; or suffering from Diabetes Mellitus should undergo further assessment prior to participating in high-intensity, very high-intensity, or competitive sports.
- A maximal exercise tolerance test (ETT) will be the initial preferred functional test<sup>9</sup>.
- In borderline or equivalent ETT results, or an uninterpretable baseline ECG (e.g. LBBB or repolarisation abnormalities), a CT coronary angiogram is recommended<sup>9</sup>.
- If further myocardial ischemia assessment is required, either an exercise stress echocardiogram or a perfusion cardiac MRI scan will be arranged.
- Invasive coronary angiography with consideration of coronary revascularisation, if there is : a significantly positive ETT, obstructive coronary artery disease on CTCA (>70% proximal stenosis of a major coronary artery vessel or > 50% left main stem stenosis) or significant ischaemic burden (stress echocardiography:  $\geq$  3 of 16 segments with stress-induced hypokinesia or akinesia; stress cardiovascular magnetic resonance:  $\geq$  2 of 16 segments with stress perfusion defects or  $\geq$  3 dobutamine-induced dysfunctional segments)<sup>9</sup>. Difficult and uncertain cases will be discussed at the Heart Team Meeting.



**Figure 2. Proposed Pre-Participation Algorithm for cardiovascular assessment in asymptomatic individuals > 40 years. Adapted from A. Pelliccia et al. ESC guidelines on Sports Cardiology<sup>9</sup>.**

## ETHICAL CONSIDERATIONS

The proposed screening programme includes all middle-aged/senior athletes and non-athletes with varying degrees of physical activity. Although it may be ethically justified to offer pre-participation screening, there are a number of ethical repercussions that can arise. For instance, the finding of significant coronary artery disease in an asymptomatic athlete can result in disqualification and significant financial loss. Similar findings in non-athletes can result in higher health and insurance premiums, and even a lack of coverage. Restriction from competitive sports or even exercise can have significant psychological distress and underscores the potential to mental health. In competitive athletes, emotions are often high not only with the individual involved but also with other stakeholders such as the team manager, coach, co-athletes, and family members, highlighting the need for collaborative decision making<sup>30</sup>.

## WORLD HEALTH ORGANISATION SCREENING CRITERIA

Health screening must meet certain criteria to be medically and financially acceptable. The most recognized criteria were determined by Wilson and Jungner in 1968, and forms the World Health

Organization standards by which screening tests are judged and determined (table 1)<sup>31</sup>. The proposed screening programme follows these standards.

**Table 1**

<b>Wilson and Jungner Criteria for Disease Screening (Adopted by the World Health Organization)</b>		
		<b>Comment</b>
1. The condition sought should be an important health problem	✓	Cardiovascular disease is a leading cause of death worldwide and accounts for up to a third of all global deaths <sup>32</sup> .
2. There should be an accepted treatment for patients with recognized disease	✓	Early primary prevention strategies for cardiovascular disease can reduce cardiovascular-related mortality and morbidity.
3. Facilities for diagnosis and treatment should be available	✓	Facilities to instigate primary and secondary prevention, and treatment strategies are available in the UK.
4. There should be a latent or early symptomatic stage	✓	Coronary atherosclerosis is a process with a long asymptomatic phase with symptom onset when coronary blood flow fails to match myocardial demand.
5. There should be a suitable test or examination	✓	Functional testing (ETT, stress echocardiogram, perfusion CMR, PET/SPECT scans), and anatomical assessment with CTCA.
6. The test should be acceptable to the population	✓	Cardiovascular risk assessment using the QRISK or SCORE models can be used to estimate cardiovascular risk.
7. The natural history of the condition, including development from latent to declared disease, should be adequately understood	✓	Coronary atherosclerosis is one of the most studied pathologies in cardiovascular medicine.
8. There should be an agreed policy on who to treat as patients	✓	Patients with significantly abnormal functional or coronary artery anatomical imaging as discussed in the text.
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole	✓	Early detection of cardiovascular disease will allow primary or even secondary prevention strategies thereby offsetting potential future cardiovascular events such as anginal symptoms, heart attacks, strokes, which can be costly to manage in the long term.
10. Case finding should be a continuing process and not a “once and for all” project From World Health Organization.	✓	If cardiovascular pathology is identified, further follow up will continue either in primary or secondary care.

## CONCLUSION

Considerable attention has focussed on screening in young athletes, whilst the risk of sudden cardiac death is higher amongst middle-aged sports participants with the greatest risk in the fifth decade. In general, inherited and congenital cardiac conditions are the most frequent cause of SCD in young athletes, while acquired heart disease, principally coronary artery disease, is most frequent in athletes of middle-aged and older. The methods of how middle-aged and older individuals should be evaluated before engaging in physical activity remain controversial and vary between counties and sporting bodies. The screening proposal discussed is based on the ESC 2020 guidelines on Sports Cardiology, which offers a pragmatic, practical, patient-centred approach. Specific investigations should be



focussed on evaluating athletes in whom clinical suspicion is raised by symptoms, family history, clinical examination, abnormalities on an ECG, baseline level of fitness and intended level of physical activity.

## References

1. C.J. Lavie et al. Exercise and the Cardiovascular System: Clinical Science and Cardiovascular Outcomes. *Circ Res.* 2015 July 3; 117(2): 207–219
2. Wahid A, Manek N, Nichols M, Kelly P, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. *J Am Heart Assoc* 2016;5:e002495.
3. Lear SA, Hu W, Rangarajan S, Gasevic D, Leong D, et al. The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. *Lancet* 2017;390:2643-2654
4. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, et al. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exercise. *N Engl J Med* 1993;329:1677–1683
5. Gherardo Finocchiaro, Michael Papadakis, Jan-Lukas Robertus, et al. Etiology of Sudden Death in Sports. Insights From a United Kingdom Regional Registry. *JACC* 2016; 67 (18): 2108-2115
6. Giri S, Thompson PD, Kiernan FJ, et al. Clinical and angiographic characteristics of exertion-related acute myocardial infarction. *JAMA* 1999;282:1731-1736.
7. Marijon E, Uy-Evanado A, Dumas F, et al. Warning symptoms are associated with survival from sudden cardiac arrest. *Ann Intern Med* 2016;164:23-29.
8. Nehme Z, Bernard S, Andrew E, et al. Warning symptoms preceding out-of-hospital cardiac arrest: do patient delays matter? *Resuscitation* 2018;123:65-70.
9. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. *European Heart Journal* (2021);42:17-96
10. Marijon E, Tafflet M, Celermajer DS, et al. Sports-related sudden death in the general population. *Circulation* 2011;124(6):672-81.
11. Chevalier L, Hajjar M, Douard H et al. Sports-related acute cardiovascular events in a general population: a French prospective study. *Eur J Cardiovasc Prev Rehabil* 2009;16(3):365-70.
12. Corrado D, Schmied C, Basso C, et al. Risk of sports: do we need a pre-participation screening for competitive and leisure athletes? *Eur Heart J* 2011 Apr;32(8):934-44.
13. Marijon E, Uy-Evanado E, Kyndaron Reinier E, et al. Sudden cardiac arrest during sports activity in middle age. *Circulation* 2015 Apr 21;131(16):1384-91.
14. <https://www.nhs.uk/conditions/nhs-health-check/>
15. <https://www.england.nhs.uk/ourwork/clinical-policy/cvd/>
16. Borjesson M, Urhausen A, Koudi E, et al. Cardiovascular evaluation of middle-aged/ senior individuals engaged in leisure-time sport activities: position stand from the sections of exercise physiology and sports cardiology of the European Association of Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2011 Jun;18(3):446-58.
17. Visseren FLJ, Mach F, Smulders YM, Carballo D, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in

clinical practice with representatives of the European Society of Cardiology and 12 medical societies  
With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart  
J. 2021 Sep 7;42(34):3227-3337

18. NICE. Lipid modification - CVD prevention. Last revised in January 2023.  
<https://cks.nice.org.uk/topics/lipid-modification-cvd-prevention/>
19. Meah MN, Dweck MR, Newby DE. Cardiovascular imaging to guide primary prevention. Heart 2020 Aug;106(16):1267-1275.
20. Detrano R, Guerci AD, Carr JJ et al. Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Group. N Engl J Med 2008; 358:1336-1345
21. Williams MC, Kwiecinski J, Doris M, et al. Low-attenuation Noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter sCoT-HeaRT trial (scottish computed tomography of the heart). Circulation 2020 May 5;141(18):1452-1462
22. Borjesson M, Drezner J. Cardiac screening: time to move forward! Br J Sports Med 2012 Nov;46 Suppl 1:i4-6.
23. SCOT-HEART Investigators, Newby DE, Adamson PD, Berry C, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med 2018 Sep 6;379(10):924-933.
24. Lahav D, Leshno M and Brezis M. Is an exercise tolerance test indicated before beginning regular exercise? A decision analysis. J Gen Intern Med 2009; 24: 934–938.
25. Rautaharju PM, Prineas RJ, Eifler WJ, et al. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. J Am Coll Cardiol 1986; 8: 1–10.
26. Leon AS and Connett J. Physical activity and 10,5 year mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol 1991; 20: 690–697.
27. Bruce RA, DeRouen TA, Hossack KF. Value of maximal exercise tests in risk assessment of primary coronary heart disease events in healthy men. Five years' experience of the Seattle heart watch study. Am J Cardiol. 1980 Sep;46(3):371-8.
28. La Gerche A, Baggish AL, Knuuti J, et al. Cardiac imaging and stress testing asymptomatic athletes to identify those at risk of sudden cardiac death. JACC Cardiovasc Imaging 2013 Sep;6(9):993-1007.
29. Magavern EF, Finocchiaro G, Sharma S et al. Time out: ethical reflections on medical disqualification of athletes in the context of mandated pre-participation cardiac screening. Br J Sports Med 2018 Sep;52(18):1207-1210.
30. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. World Health Organization Public Health Papers, No. 34; 1968. [http://whqlibdoc.who.int/php/WHO\\_PHP\\_34.pdf](http://whqlibdoc.who.int/php/WHO_PHP_34.pdf)
31. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))